Articles From: EP Energy Provides 2015 Outlook Estimates Supported by High Quality Assets, Efficient Operations and Strong Hedge Positions to Epizyme Elects Kenneth Bate to Board of Directors


2015/2/13
HOUSTON , Feb.
Sign-up for EP Energy to Provide 2014 Results and 2015 Outlook investment picks
2014/12/9
VANCOUVER , Dec.
Sign-up for EPA Issues Draft Underground Injection Control Permit to Florence Copper investment picks
2014/12/22
http://www.marketwire.com/library/MwGo/2014/12/22/11G029088/EPIC_Corporation-949224062297.jpg AUSTIN, TX--(Marketwired - December 22, 2014) - EPIC Corporation Inc. (OTC PINK: EPOR) and Ronald Tucker, its CEO, announced, "EPIC's Board of Directors has authorized an offer to exchange shares of its Series A 5% Convertible Preferred Stock for common stock.
Sign-up for EPIC Offers a Second Exchange of Its Series A Preferred Stock in Place of Its Announced Dividend Policy investment picks
2015/1/12
http://www.marketwire.com/library/MwGo/2015/1/12/11G030114/EPIC_Corporation-949224062297.jpg AUSTIN, TX--(Marketwired - January 12, 2015) - EPIC Corporation Inc. (OTC PINK: EPOR) and Ronald Tucker it CEO announced "EPIC's Board of Directors has authorized a series of quarterly exchange offerings for its common shareholders in street name to exchange common shares for preferred shares.
Sign-up for Epic Offers Common Shareholders Three Methods to Receive a Return on Investment, One Method Could Provide a 500% to 888% Annualized Rate of Return investment picks
2015/1/28
Epic Snow and Deals at Vail and Beaver Creek Await Canadian Travelers Canada NewsWire - Get 45 percent off a seven-night luxury stay at The Arrabelle at Vail Square, A RockResort, plus 10 percent off direct flights from Toronto to Eagle Airport - Package coincides with 2015 FIS Alpine World Ski Championships BROOMFIELD, Colo.
Sign-up for Epic Snow and Deals at Vail and Beaver Creek Await Canadian Travelers investment picks
2015/1/22
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems and Contoural Announce Global Partnership to Deliver Information Governance Solutions investment picks
2015/1/12
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems Appoints President and Chief Operating Officer Brad D. Scott to Board of Directors investment picks
2015/1/7
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems Names Andrew Shimek as Managing Director, Global eDiscovery Solutions investment picks
2014/12/15
KANSAS CITY, Kan., Dec.
Sign-up for Epiq Systems Names Chris Jutkiewicz Senior Vice President and Chief Technology Officer to Strengthen Global Technology Footprint investment picks
2015/1/12
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems to Host Webcast on Data Security on January 15, 2015 investment picks
2015/2/10
KANSAS CITY, Kan., Feb.
Sign-up for Epiq Systems to Report 2014 Results and Host Call on Monday, March 2nd at 4:30 pm ET investment picks
2015/1/26
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today that it has commenced an underwritten public offering of shares of its common stock.
Sign-up for EPIRUS Announces Proposed Public Offering of Common Stock investment picks
2014/12/2
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS ), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced the launch of its first product, Infimab (BOW015), the first infliximab biosimilar in India.
Sign-up for EPIRUS Biopharmaceuticals Remicade® Biosimilar, Infimab™, Launches in India investment picks
2015/2/5
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the Company is scheduled to present a corporate overview at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. Eastern Time.
Sign-up for EPIRUS Biopharmaceuticals to Present at Leerink Global Healthcare Conference investment picks
2015/1/20
ADVISORY, Jan.
Sign-up for EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) to Ring The Nasdaq Stock Market Closing Bell investment picks
2015/1/30
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today the pricing of an underwritten public offering of 9.6 million shares of its common stock, offered at a price to the public of $5.00 per share.
Sign-up for EPIRUS Prices $48 Million Public Offering of Common Stock investment picks
2015/2/12
http://www.ccnmatthews.com/logos/20080922-epistem200.jpg MANCHESTER, UNITED KINGDOM --
Sign-up for Epistem Announces the Successful Evaluation of New RNA-AMP(TM) (RNA-Amplification) Technology investment picks
2015/2/16
EPIX and DISH Network L.L.C. have reached a multi-year renewal agreement for continued carriage of EPIX to DISH customers.
Sign-up for EPIX and DISH Renew Carriage Agreement investment picks
2015/1/29
Premium entertainment network EPIX celebrates Golden Globe® winners and Academy Award® Nominees with an encore primetime marathon of Hollywood Sessions February 9 through February 13 at 8pm ET/PT, 7C , to coincide with the return of Oscar® ballots.
Sign-up for EPIX Celebrates Golden Globe® Winners and Academy Award® Nominees with Primetime Marathon of Hollywood Sessions investment picks
2015/1/21
Premium TV network EPIX announced today that its Original Documentary Deep Web , chronicling one of the most important and riveting digital crime sagas of the century -- the October 2013 arrest of Ross William Ulbricht --
Sign-up for EPIX Documentary Investigates the Arrest of Ross Ulbricht, the Alleged “Dread Pirate Roberts” -- Founder of Online Black Market Silk Road, in the Original Documentary “Deep Web” investment picks
2015/1/13
EPIX, the first premium entertainment network created to capitalize on the “TV Everywhere” era, today announced that it has named Jocelyn Diaz, former Vice President of Production at Walt Disney Studios, as Executive Vice President for Original Programming.
Sign-up for EPIX Names Jocelyn Diaz as Executive Vice President for Original Programming investment picks
2015/1/26
EPIX Presents Road To the NHL Stadium Series™ brought to you by Coors Light will make its U.S. Television Premiere on EPIX February 3 at 10pm ET/PT, 9C with four weekly episodes focused on the reigning Stanley Cup® Champion Los Angeles Kings and their division rivals, the San Jose Sharks, as they prepare for the 2015 Coors Light NHL Stadium Series™ at Levi’s® Stadium in Santa Clara, California on Saturday, February 21.
Sign-up for EPIX Presents Road To the NHL Stadium Series™ brought to you by Coors Light U.S. Television Premiere on February 3 at 10pm ET/PT, 9C investment picks
2015/2/10
Premium TV network EPIX announced today that stand-up’s biggest and most off-the-wall comics Jim Norton, Jim Breuer and Lisa Lampanelli will star in three new hour-long Original Comedy Events.
Sign-up for EPIX Takes a New Slate of Comedy Programming to the Stage Starring Some of Today’s Wittiest and Most Cutting-Edge Stand-Up Comics investment picks
2015/2/3
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th.
Sign-up for Epizyme Appoints Andrew Singer as Chief Financial Officer investment picks
2015/1/29
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Robert A.
Sign-up for Epizyme Appoints Robert A. Copeland, Ph.D., as President of Research investment picks
2014/12/8
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). Epizyme, along with its partner Celgene, is developing EPZ-5676 for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The trial found that EPZ-5676 was generally safe and well tolerated across all dose cohorts and showed clinical and biological activity.
Sign-up for Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial investment picks
2014/12/12
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent consultant in the biotechnology industry, has been elected to the Company’s board of directors.
Sign-up for Epizyme Elects Kenneth Bate to Board of Directors investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: EP Energy Provides 2015 Outlook Estimates Supported by High Quality Assets, Efficient Operations and Strong Hedge Positions to Epizyme Elects Kenneth Bate to Board of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent